Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tilmann Bochtler

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Blood|February 29, 2008
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instabilityTilmann Bochtler, Ute Hegenbart, Friedrich W Cremer, et al.
Journal of Hematology & Oncology|April 27, 2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Francesco Saraceni, Myriam Labopin, Arne Brecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemiaTilmann Bochtler, Friedrich Stölzel, Christoph E Heilig, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 22, 2026
<sup>68</sup>Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of <sup>68</sup>Ga-FAPI-46 with <sup>18</sup>F-FDG in 13 patientsAnna-Maria Spektor, Sergio Armando Zapata Bonilla, Philipp Mildenberger, et al.
Blood|February 12, 2011
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
The Oncologist|March 9, 2021
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial ExperienceChantal Pauli, Tilmann Bochtler, Linda Mileshkin, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
International Journal of Cancer|January 24, 2020
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primaryTilmann Bochtler, Anna Reiling, Volker Endris, et al.
Blood Advances|October 18, 2018
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myelomaTilmann Bochtler, Maximilian Merz, Thomas Hielscher, et al.
Cancers|September 8, 2019
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer SamplesMartina Kirchner, Olaf Neumann, Anna-Lena Volckmar, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Blood|February 29, 2008
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instabilityTilmann Bochtler, Ute Hegenbart, Friedrich W Cremer, et al.
Journal of Hematology & Oncology|April 27, 2019
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)Francesco Saraceni, Myriam Labopin, Arne Brecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemiaTilmann Bochtler, Friedrich Stölzel, Christoph E Heilig, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 22, 2026
<sup>68</sup>Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of <sup>68</sup>Ga-FAPI-46 with <sup>18</sup>F-FDG in 13 patientsAnna-Maria Spektor, Sergio Armando Zapata Bonilla, Philipp Mildenberger, et al.
Blood|February 12, 2011
Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler, Ute Hegenbart, Christiane Heiss, et al.
The Oncologist|March 9, 2021
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial ExperienceChantal Pauli, Tilmann Bochtler, Linda Mileshkin, et al.
Haematologica|May 20, 2017
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow upUte Hegenbart, Tilmann Bochtler, Axel Benner, et al.
International Journal of Cancer|January 24, 2020
Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primaryTilmann Bochtler, Anna Reiling, Volker Endris, et al.
Blood Advances|October 18, 2018
Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myelomaTilmann Bochtler, Maximilian Merz, Thomas Hielscher, et al.
Cancers|September 8, 2019
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer SamplesMartina Kirchner, Olaf Neumann, Anna-Lena Volckmar, et al.
Pageof 6